HIMS Stock Price Today (October 2026) — Hims & Hers Health, Inc. Analysis & Key Metrics 2026-10-20
Hims & Hers Health, Inc. (HIMS) is trading at $29.21, up 3.77% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $31.15 (6.6% upside).
- Volatility is high (58.35% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (38.20% YoY) alongside competitive pressures in the Drug Manufacturers - Specialty & Generic space.
HIMS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Hims & Hers Health, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $7.52B
P/E Ratio
Forward P/E: 29.51
Revenue Growth
Year over Year
Analyst Target
+6.6% upside potential
Key Investor Questions About HIMS
What investors need to know before buying
Based on current market data, HIMS presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 50.93)
- Fundamentals say: Caution warranted (high leverage concerns)
HIMS's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for HIMS investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $1.55B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, HIMS stock traded between $13.74 and $57.45 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 58.35% annualized volatility and β=2.64, the stock exhibits high sensitivity to market moves—making HIMS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Hims & Hers Stock Jumps on Major European Expansion
What Are Hims & Hers Health Stock Bears Missing?
Hims & Hers Health (HIMS) Dropped, So What Is Driving Attention Now?
Peptide Rule Change Could Matter For Hims Shares (HIMS)
Latest TickZen Insights
All insights →No TickZen article on HIMS yet. Our newest analysis:
Explore More Analysis for HIMS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Hims & Hers Health, Inc.
Hims & Hers Health, Inc. (HIMS) is currently trading at $29.21. The RSI (14-day) is at 50.9, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $31.15 implies 6.6% upside from current levels. Volatility is high at 58.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Hims & Hers Health, Inc. (HIMS): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 29.51. The PEG ratio is 2.15, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 20.74. Price-to-Sales is 2.51. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering HIMS, the consensus price target is $31.15. This represents a 6.6% upside from the current price of $29.21. The range spans from a low target of $23.00 to a high target of $42.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Hims & Hers Health, Inc. (HIMS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Hims & Hers Health, Inc. (HIMS) investors include: 1. High volatility (58.4% annualized)—the stock can experience significant daily price swings. 2. Elevated debt levels (debt-to-equity of 4.77x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Elevated short interest (28.2% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Hims & Hers Health, Inc.'s (HIMS) current debt and financial health profile: Total debt stands at $1.55B. The debt-to-equity ratio is 4.77x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 0.93, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.82. The company holds $841.05M in cash and equivalents. Free cash flow is positive at $849.44M, providing a cushion for debt servicing and shareholder returns.